Pharmaceutical

Arcus Biosciences obtains loan facility with Hercules Capital worth $250m

Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.

Aug 29, 2024 - 04:00
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.
Read the original article

Tags:

Previous Article

Bayer teams up with lncRNA-focused NextRNA in $547m deal

Next Article

Soleno wins FDA priority review for Prader-Willi therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants

Sanofi begins shipping BEYFORTUS to US for RSV preventi...

Sep 18, 2024

STAT+: U.S. Anesthesia Partners, Welsh Carson face class action over monopoly allegations

STAT+: U.S. Anesthesia Partners, Welsh Carson face clas...

Nov 23, 2023

To build trust among LA’s unhoused, a street medicine team turns to technology

To build trust among LA’s unhoused, a street medicine t...

Apr 5, 2023